4//SEC Filing
Hewes L. Becker 4
Accession 0001415889-24-015315
CIK 0001597264other
Filed
Jun 3, 8:00 PM ET
Accepted
Jun 4, 4:00 PM ET
Size
25.7 KB
Accession
0001415889-24-015315
Insider Transaction Report
Form 4
Hewes L. Becker
CHIEF MEDICAL OFFICER
Transactions
- Sale
Common Stock
2024-06-03$106.43/sh−1,951$207,645→ 31,938 total - Exercise/Conversion
Stock Options (Right to Buy)
2024-05-31−10,573→ 13,490 totalExercise: $66.24Exp: 2030-06-01→ Common Stock (10,573 underlying) - Exercise/Conversion
Stock Options (Right to Buy)
2024-05-31−5,729→ 19,271 totalExercise: $43.15Exp: 2033-03-01→ Common Stock (5,729 underlying) - Exercise/Conversion
Common Stock
2024-05-31$61.31/sh+8,385$514,084→ 65,239 total - Exercise/Conversion
Common Stock
2024-05-31$66.24/sh+10,573$700,356→ 56,854 total - Sale
Common Stock
2024-05-31$106.50/sh−3,191$339,842→ 64,106 total - Exercise/Conversion
Stock Options (Right to Buy)
2024-05-31−8,385→ 9,115 totalExercise: $61.31Exp: 2032-03-01→ Common Stock (8,385 underlying) - Sale
Common Stock
2024-05-31$105.81/sh−20,904$2,211,852→ 43,202 total - Sale
Common Stock
2024-06-03$106.43/sh−2,971$316,204→ 33,889 total - Exercise/Conversion
Common Stock
2024-05-31$43.15/sh+5,729$247,206→ 70,968 total - Sale
Common Stock
2024-05-31$107.86/sh−3,671$395,954→ 67,297 total - Sale
Common Stock
2024-05-31$104.83/sh−6,342$664,832→ 36,860 total
Footnotes (9)
- [F1]Effected pursuant to a trading plan adopted on March 1, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $107.50 to $108.31 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (5) in this form 4.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $106.24 to $107.20 per share.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $105.22 to $106.20 per share.
- [F5]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $104.43 to $105.20 per share.
- [F6]The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
- [F7]This option was granted on June 1, 2020. This option vested with respect to 25% of the shares underlying the option on June 1, 2021 and as to an additional 1/48th of the shares underlying the option each month thereafter.
- [F8]This option was granted on March 1, 2022. This option vested with respect to 1/48th of the shares underlying the option on April 1, 2022 and as to an additional 1/48th of the shares underlying the option each month thereafter.
- [F9]This option was granted on March 1, 2023. This option vested with respect to 1/48th of the shares underlying the option on April 1, 2023 and as to an additional 1/48th of the shares underlying the option each month thereafter.
Documents
Issuer
Blueprint Medicines Corp
CIK 0001597264
Entity typeother
Related Parties
1- filerCIK 0001840110
Filing Metadata
- Form type
- 4
- Filed
- Jun 3, 8:00 PM ET
- Accepted
- Jun 4, 4:00 PM ET
- Size
- 25.7 KB